Evaluating the prevalence and severity of metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes mellitus in primary care
Journal of Internal Medicine · 2025-09 · 298 (3) · 173-187
DOI: 10.1111/joim.20103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Internal Medicine, online erschienen am 16.06.2025. Verfasst von Wile Balkhed und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Fatty Liver. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences, Mag-TarmFonden, Swedish Gastroenterology Society, Bengt Ihres Foundation.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background and aims The prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) has increased during the epidemic of obesity. Type 2 diabetes mellitus (T2DM) is associated with progressive MASLD. Therefore, many guidelines recommend screening for MASLD in patients with T2DM. Most studies in patients with MASLD have been conducted in specialist care. We investigated the prevalence and severity of MASLD in patients with T2DM from primary care.
Methods
Patients with T2DM were prospectively included from primary care facilities to undergo transient elastography with controlled attenuation parameter and whole‐body magnetic resonance imaging (MRI) to assess liver fat, cardiac function, muscle composition, and distribution of body fat.
Results
Among 308 participants, 59% had MASLD, 7% had suspected advanced fibrosis (transient elastography ≥ 10 kPa), and 1.9% had cirrhosis. The mean age was 63.9 ± 8.1 years; 37% were female, with no differences between the MASLD and the non‐MASLD groups. Participants with MASLD had greater body mass index (31.1 ± 4.4 vs. 27.4 ± 4.1 kg/m 2 , p < 0.001) and a higher prevalence of obesity (60% vs. 21%, p < 0.001). Obesity increased the risk of fibrotic MASLD eightfold, as confirmed by multivariable analysis. Participants with MASLD also had increased visceral and abdominal subcutaneous adipose tissue and muscle fat infiltration. On cardiac MRI, participants with MASLD had a lower left ventricular (LV) stroke volume index, a lower LV end‐diastolic volume index, and an increased LV concentricity.
Conclusions
In this cohort of primary care patients with T2DM, 59% had MASLD, and 7% had suspected advanced fibrosis. Obesity was a strong predictor of fibrotic MASLD. MASLD was associated with alterations to the left ventricle and increased deposition of ectopic fat.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
- Primary Health Care Center, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
- Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
- Wallenberg Center for Molecular Medicine (WCMM), Linköping University, Linköping, Sweden.
- Center for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, Sweden.
- AMRA Medical AB, Linköping, Sweden.
ORCID-Profile: Wile Balkhed, Martin Bergram, Fredrik Iredahl, Carl Edin, Carl-Johan Carlhäll, Tino Ebbers, Pontus Henriksson, Karin Rådholm, Gunnar Cedersund, Mikael Forsgren, Olof Dahlqvist Leinhard, Cecilia Jönsson, Peter Lundberg, Stergios Kechagias, Nils Dahlström, Patrik Nasr, Mattias Ekstedt
Förderung
- Gilead Sciences
- Mag-TarmFonden, Swedish Gastroenterology Society
- Bengt Ihres Foundation
- Svenska Läkaresällskapet
- Knut och Alice Wallenbergs Stiftelse
- Region Östergötland
- Ruth och Richard Julins Stiftelse
- Wallenberg Centre for Molecular and Translational Medicine
Zitieren
APA
Balkhed, W., Bergram, M., Iredahl, F., Holmberg, M., Edin, C., Carlhäll, C. J., Ebbers, T., Henriksson, P., Simonsson, C., Rådholm, K., Cedersund, G., Forsgren, M., Leinhard, O. D., Jönsson, C., Lundberg, P., Kechagias, S., Dahlström, N., Nasr, P., & Ekstedt, M. (2025). Evaluating the prevalence and severity of metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes mellitus in primary care. Journal of Internal Medicine, 298(3), 173-187. https://doi.org/10.1111/joim.20103
Vancouver
Balkhed W, Bergram M, Iredahl F, Holmberg M, Edin C, Carlhäll CJ, et al. Evaluating the prevalence and severity of metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes mellitus in primary care. Journal of Internal Medicine. 2025;298(3):173-187. doi:10.1111/joim.20103
BibTeX
@article{Balkhed2025,
author = {Balkhed, Wile and Bergram, Martin and Iredahl, Fredrik and Holmberg, Markus and Edin, Carl and Carlhäll, Carl-Johan and Ebbers, Tino and Henriksson, Pontus and Simonsson, Christian and Rådholm, Karin and Cedersund, Gunnar and Forsgren, Mikael and Leinhard, Olof Dahlqvist and Jönsson, Cecilia and Lundberg, Peter and Kechagias, Stergios and Dahlström, Nils and Nasr, Patrik and Ekstedt, Mattias},
title = {Evaluating the prevalence and severity of metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes mellitus in primary care},
journal = {Journal of Internal Medicine},
year = {2025},
volume = {298},
number = {3},
pages = {173--187},
doi = {10.1111/joim.20103}
}
EUVIMED